Clinical trials: SARS
Biological Availability, Healthy Participants
A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants
Medicines that may have different names or be made in different ways but have the same effect on the body are called bioequivalent.
- Trial name
- NCT06397144
- Testing
- Paxlovid, Nirmatrelvir/ritonavir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.
- Trial name
- COVID-19 (NCT06008860)
- Testing
- Experimental: Primary Cohort
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
This is a Phase 2/3, randomized, placebo-controlled, multi-center trial to evaluate the safety, immunogenicity and efficacy of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA®…
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
- Trial name
- NCT04642638
- Testing
- INO-4800, CELLECTRA® 2000
- Where
- 27 sites in United States, Colombia and 1 more
- Volunteers
- 1,307 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
SARS-CoV Infection, Covid19
Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19)
The pandemic caused by SARS-CoV-2 is a global emergency present in 6 continents including 66 countries, incurring a shortage of effective and safe therapeutic alternatives that can contribute to reducing the risk of…
- Conditions
- SARS-CoV Infection, Covid19, Infection Viral
- Trial name
- NCT04684550
- Testing
- Stabilized hypochlorous acid
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hospital Universitario San Ignacio
COVID-19 Pandemic, Immunogenicity
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
Under protocol versions 1.01-1.06: The five recently emerged SARS-CoV2 variants that were designated as VOCs are the Alpha variant, Beta variant, Gamma variant, Delta variant and the Omicron variant.
- Conditions
- COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection, COVID-19
- Trial name
- SH-MO-214 (NCT05383560)
- Testing
- mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, MRNA-1273.222 Vaccine
- Where
- Israel
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Vaccine Reaction
(VIII): The Eight Study and Immunologic Response Sub-study
The study's objective is to test the hypothesis that immune system activation and subsequent systemic inflammation can be detected through continuously tracking multiple bio signals including physiologic variables (ECG, skin…
- Trial name
- NCT05237024
- Where
- 2 sites in United States, Canada
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- physIQ, Inc.
COVID-19, SARS-CoV-2 Infection
Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
A phase Ⅱ, observer-blind, randomized, controlled, investigator-initiated clinical trial to evaluate the safety and immunogenicity of a booster vaccination with Recombinant COVID-19 vaccine (Sf9 Cell) in a population aged 18…
- Trial name
- NCT05463354
- Testing
- Recombinant COVID-19 Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Philippines
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19
A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)
This study will determine the immunogenicity of Spikogen in vaccine naïve individuals. Spikogen will be administered as two doses 1 month apart with a third booster dose either 1 or 3 months after the second dose.
- Trial name
- NCT05279456
- Testing
- Advax-CpG55.2 adjuvanted recombinant spike protein
- Where
- Australia
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Coronavirus Infections, Severe Acute Respiratory Syndrome
Household Transmission Investigation Study for COVID-19 in Tropical Regions
This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed…
- Conditions
- Coronavirus Infections, Severe Acute Respiratory Syndrome, SARS-CoV Infection
- Trial name
- EPI-COVID-19 (NCT04328129)
- Testing
- Human biological samples
- Where
- 4 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
Covid19
Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
People who inject drugs (PWID) experience disproportionate risk of being infected with SARS-CoV-2, the virus that causes COVID-19, yet due to stigma, fear of mistreatment, and other factors, PWID are far less likely to be…
- Trial name
- NCT04924803
- Testing
- No video, Video Text
- Where
- United States
- Volunteers
- 545 people, healthy volunteers welcome
- Sponsor
- NDRI-USA, Inc.
SARS-CoV-2 Infection
Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19
The purpose of this study is to compare the risks of COVID-19 in individuals from Chicagoland communities randomized to low (400 IU/day) vs. moderate (4,000 IU/day) or high (10,000 IU/day) dose vitamin D.
- Trial name
- NCT04868903
- Testing
- Vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 1,475 people, healthy volunteers welcome
- Sponsor
- University of Chicago
SARS-CoV 2, Immunization; Infection
Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.
Infections with Corona-Viruses have shown to be a menace for patients with comorbidities such as hypertension, diabetes, cardiovascular disease or immunosuppression.
- Trial name
- CONEC (NCT04347694)
- Where
- Austria
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
COVID-19
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years
This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine (CoronaVac)manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05112913
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2
- Where
- China
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
SARS Coronavirus (SARS-CoV-2) Infection
A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19
This study is to gain critical knowledge to understand the factors influencing the outcome of a pandemic virus within the city of Basel.
- Trial name
- NCT04351503
- Testing
- Study A, Study B, Study C
- Where
- 6 sites in Switzerland
- Volunteers
- 126,586 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
COVID-19 Prevention
Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light
The study Global sponsor is planning several parallel studies of Sputnik-Light vector vaccine across the globe in United Arab Emirates, Russia and possibly in other countries in case of confirmation associated with the same…
- Trial name
- SPUTNIK-LIGHT (NCT04741061)
- Testing
- Sputnik Light
- Where
- 15 sites in Russia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Covid19
COVID-19 Nasal Swab Trial
The purpose of this trial is to compare 2 types of nasonasopharyngeal swabs (a new design to a conventional nylon-flocked nasopharyngeal swab) for effectiveness.
- Trial name
- NCT04649424
- Testing
- CanSwab
- Where
- 2 sites in Canada
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Orthopaedic Innovation Centre
Coronavirus (SARS-CoV)
SARS Coronavirus Vaccine (SARS-CoV)
Severe acute respiratory syndrome (SARS) is a viral illness that affects the respiratory (breathing) system. The purpose of this study is to evaluate the safety and protective (immune) responses to different doses of a SARS…
- Trial name
- NCT00533741
- Testing
- Aluminum hydroxide, SARS-CoV
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunization, Healthy Volunteers
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60…
- Conditions
- Immunization, Healthy Volunteers, COVID-19 Immunization, Influenza Immunization
- Trial name
- NCT07890454
- Testing
- IIV-HD (standalone), NVXC19 (EU licensed, standalone), IIV-HD + NVXC19 combination
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.